Industry
Biotechnology
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Loading...
Open
1.01
Mkt cap
42M
Volume
331K
High
1.03
P/E Ratio
-0.62
52-wk high
1.93
Low
0.90
Div yield
N/A
52-wk low
0.49
Portfolio Pulse from
November 07, 2024 | 2:30 pm
Portfolio Pulse from Benzinga Insights
October 30, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 3:07 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 1:25 pm
Portfolio Pulse from Benzinga Newsdesk
September 13, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 12:48 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 11:45 am
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 11:42 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.